DK3564378T3 - Immunogen sammensætning - Google Patents

Immunogen sammensætning Download PDF

Info

Publication number
DK3564378T3
DK3564378T3 DK19179871.9T DK19179871T DK3564378T3 DK 3564378 T3 DK3564378 T3 DK 3564378T3 DK 19179871 T DK19179871 T DK 19179871T DK 3564378 T3 DK3564378 T3 DK 3564378T3
Authority
DK
Denmark
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
DK19179871.9T
Other languages
English (en)
Other versions
DK3564378T5 (da
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3564378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK3564378T3 publication Critical patent/DK3564378T3/da
Publication of DK3564378T5 publication Critical patent/DK3564378T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK19179871.9T 2011-05-27 2012-05-25 Immunogen sammensætning DK3564378T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161490716P 2011-05-27 2011-05-27
US201161490707P 2011-05-27 2011-05-27
US201161490734P 2011-05-27 2011-05-27
EP16193340.3A EP3138916B1 (en) 2011-05-27 2012-05-25 Immunogenic composition

Publications (2)

Publication Number Publication Date
DK3564378T3 true DK3564378T3 (da) 2024-01-08
DK3564378T5 DK3564378T5 (da) 2024-09-02

Family

ID=46168484

Family Applications (4)

Application Number Title Priority Date Filing Date
DK12726374.7T DK2714911T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning.
DK16193340.3T DK3138916T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK12724950.6T DK2714910T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK19179871.9T DK3564378T5 (da) 2011-05-27 2012-05-25 Immunogen sammensætning

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK12726374.7T DK2714911T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning.
DK16193340.3T DK3138916T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning
DK12724950.6T DK2714910T3 (da) 2011-05-27 2012-05-25 Immunogen sammensætning

Country Status (25)

Country Link
US (5) US9409974B2 (da)
EP (6) EP3327126A1 (da)
JP (3) JP2014516532A (da)
KR (1) KR102014502B1 (da)
CN (3) CN103732750A (da)
BR (2) BR112013030395B1 (da)
CA (2) CA2837395C (da)
CY (3) CY1118599T1 (da)
DK (4) DK2714911T3 (da)
EA (1) EA030898B1 (da)
ES (4) ES2743442T3 (da)
FI (1) FI3564378T3 (da)
HR (4) HRP20231749T1 (da)
HU (4) HUE044772T2 (da)
IL (1) IL229529B2 (da)
LT (4) LT3138916T (da)
ME (1) ME02600B (da)
MX (1) MX346200B (da)
PL (4) PL2714911T3 (da)
PT (4) PT2714911T (da)
RS (1) RS55605B1 (da)
SG (1) SG195037A1 (da)
SI (4) SI3564378T1 (da)
SM (1) SMT201700110B (da)
WO (3) WO2012163817A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP3513806B1 (en) 2012-12-05 2023-01-25 GlaxoSmithKline Biologicals SA Immunogenic composition
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
WO2016131157A1 (en) 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CN112703006A (zh) * 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP1041149B8 (en) 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
NZ312502A (en) * 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
WO2012163817A2 (en) 2012-12-06
EP3327126A1 (en) 2018-05-30
WO2012163817A3 (en) 2013-03-21
PT3138916T (pt) 2019-09-17
CY1121936T1 (el) 2020-10-14
ES2615737T3 (es) 2017-06-08
CN103717742B (zh) 2018-05-22
PL3564378T3 (pl) 2024-03-11
BR112013030395A2 (pt) 2016-12-13
EP3564378A1 (en) 2019-11-06
EP2714910B1 (en) 2018-01-10
HUE030823T2 (en) 2017-06-28
HUE037126T2 (hu) 2018-08-28
US9290565B2 (en) 2016-03-22
PT3564378T (pt) 2024-01-26
SI2714911T1 (sl) 2017-03-31
WO2012163811A1 (en) 2012-12-06
US9644024B2 (en) 2017-05-09
PT2714911T (pt) 2017-02-06
EP3564378B1 (en) 2023-11-01
LT3138916T (lt) 2019-08-26
SI3138916T1 (sl) 2019-08-30
SI2714910T1 (en) 2018-04-30
PT2714910T (pt) 2018-03-09
KR20140019848A (ko) 2014-02-17
KR102014502B1 (ko) 2019-08-26
CY1119916T1 (el) 2018-06-27
CN103717742A (zh) 2014-04-09
CA2837395A1 (en) 2012-12-06
ES2968455T3 (es) 2024-05-09
MX346200B (es) 2017-03-10
US10093722B2 (en) 2018-10-09
HRP20180339T1 (hr) 2018-03-23
HRP20191291T1 (hr) 2019-10-18
EA030898B1 (ru) 2018-10-31
LT2714910T (lt) 2018-03-12
EP2714911B1 (en) 2016-11-30
PL2714911T3 (pl) 2017-05-31
HUE044772T2 (hu) 2019-11-28
US9409974B2 (en) 2016-08-09
HUE064492T2 (hu) 2024-03-28
JP2014516532A (ja) 2014-07-17
US20140093529A1 (en) 2014-04-03
DK3564378T5 (da) 2024-09-02
CN103732750A (zh) 2014-04-16
JP2017012160A (ja) 2017-01-19
CY1118599T1 (el) 2017-07-12
EP2714910A1 (en) 2014-04-09
ES2660468T3 (es) 2018-03-22
DK2714910T3 (da) 2018-02-05
MX2013013924A (es) 2013-12-16
US20170362309A1 (en) 2017-12-21
US10377816B2 (en) 2019-08-13
US20170247421A1 (en) 2017-08-31
FI3564378T3 (fi) 2024-01-18
IL229529B1 (en) 2023-01-01
US20140178424A1 (en) 2014-06-26
BR112013030395B1 (pt) 2022-11-01
EP4296361A3 (en) 2024-02-28
SI3564378T1 (sl) 2024-02-29
PL2714910T3 (pl) 2018-06-29
JP5952390B2 (ja) 2016-07-13
HRP20231749T1 (hr) 2024-03-15
WO2012163810A1 (en) 2012-12-06
EA201391548A1 (ru) 2014-06-30
EP3138916B1 (en) 2019-06-19
IL229529A0 (en) 2014-01-30
HRP20170094T1 (hr) 2017-03-24
CA2837393A1 (en) 2012-12-06
ES2743442T3 (es) 2020-02-19
PL3138916T3 (pl) 2019-11-29
EP2714911A2 (en) 2014-04-09
RS55605B1 (sr) 2017-06-30
SG195037A1 (en) 2013-12-30
DK2714911T3 (da) 2017-02-27
EP3138916A1 (en) 2017-03-08
US20160159867A1 (en) 2016-06-09
LT2714911T (lt) 2017-02-10
LT3564378T (lt) 2024-01-25
BR112013030396A2 (pt) 2016-12-13
CA2837395C (en) 2021-05-18
DK3138916T3 (da) 2019-08-26
IL229529B2 (en) 2023-05-01
EP4296361A2 (en) 2023-12-27
CN107098977A (zh) 2017-08-29
SMT201700110B (it) 2017-03-08
ME02600B (me) 2017-06-20
JP2014522238A (ja) 2014-09-04

Similar Documents

Publication Publication Date Title
SMT201700110B (it) Composizione immunogena
DK3513806T3 (da) Immunogen sammensætning
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
DK3170508T3 (da) Vaccineformuleringer
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
DK3023106T3 (da) Mycobacterium-antigensammensætning
DK2402032T3 (da) Immunogen sammensætning
SMT201600082B (it) Vaccino pcsk9
BR112013033808A2 (pt) composição
DK2609931T3 (da) Immunogen sammensætning
BR112014000015A2 (pt) formulação
BR112014007030A2 (pt) composição
FR2978964B1 (fr) Composition vaccinale anti-il-6
DK2938356T3 (da) Immunogen sammensætning som omfatter mycoplasma-antigener
DK2672817T3 (da) Forbedrede insekticide formuleringer
BR112014011723A2 (pt) composição antiperspirante
CR20140186A (es) Composiciones mejoradas
SMT201600415B (it) Procedimento di preparazione di metaxalone
DK2726579T3 (da) Sammensætning
BR112014009167A2 (pt) implante nuclear